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Abstract 
Ischemic heart disease remains the leading cause of death worldwide. Ischemic pre-, post-, and remote 
conditionings trigger endogenous cardioprotection that renders the heart resistant to ischemic–reperfusion 
injury (IRI). Mimicking endogenous cardioprotection bymodulating genes involved in cardioprotective signal 
transduction provides an opportunity to reproduce endogenous cardioprotection with better possibilities of 
translation into the clinical setting. Genes and signaling pathways by which conditioning maneuvers exert their 
effects on the heart are partially understood. This is due to the targeted approach that allowed identifying one 
or a few genes associated with IRI and cardioprotection. Genes critical for signaling pathways in 
cardioprotection include protectomiRs (e.g., microRNA 125b*), ZAC1 transcription factor, pro-inflammatory 
genes such as cycloxygenase (COX)-2 and inducible nitric oxide synthase (iNOS), antioxidant enzymes such as 
hemoxygenase (HO)-1, extracellular and manganese superoxidase dismutases (ec-SOD and Mg-SOD), heat 
shock proteins (HSPs), growth factors such as insulin like growth factor (IGF)-1 and hepatocyte growth factor 
(HGF), antiapoptotic proteins such as Bcl-2 and Bcl-xL, pro-apoptotic proteins such as FasL, Bcl-2, Bax, caspase-
3 and p53, and proangiogenic genes such as TGFbeta, sphingosine kinase 1 (SPK1), and PI3K–Akt. By identifying 
the gene expression profiles of IRI and ischemic conditioning, one may reveal potential gene targets 
responsible for cardioprotection. In this manuscript, we review the current state of the art of gene therapy in 
cardioprotection and propose that gene expression analysis facilitates the identification of individual genes 
associated with cardioprotection. We discuss signaling pathways associated with cardioprotection that can be 
targeted by gene therapy to achieve cardioprotection. 
 
Introduction 
Ischemia/reperfusion injury (IRI) including myocardial infarction and its long termconsequences aremajor 
causes of morbidity andmortality worldwide. Although early mechanical reperfusion therapy dramatically 
increases survival of acute infarction patients, cardioprotective drug therapy is still an unmet clinical need. 
Ischemic pre-, post-, and remote conditioning, are potential therapeutic strategies for protecting organs 
against the detrimental effects of acute IRI. Mimicking ischemic cardiac conditioning through prophylactic 
transfection of cardioprotective genes into the myocardium would represent a therapeutic tool to protect the 
heart throughout an ischemia/reperfusion episode. A thorough knowledge of the genes and signaling pathways 
associatedwith IRI and ischemic conditioning are a prerequisite for the development of cardioprotective gene 
therapy [1]. (See Fig. 1.) 
 
 
Fig. 1. Target genes and mechanisms of cardioprotection. Abbreviations: HGF, hepatocyte growth factor; IGF, insulin like growth factor; 
PR39, proline 39; HSP70, heat shock protein 70; iNOS inducible nitric oxide synthase; ec-SOD, superoxide dismutase; HO-1, 
hemoxygenase 1; HIF-1, hypoxia inducible factor 1; TGFbeta, tumor growth factor beta; SPK1, sphingosine kinase 1. 
1.1. Cardioprotection by ischemic conditioning of the heart 
During ischemic pre-, post- and remote conditioning, cytoprotective cellular mechanisms are activated by brief 
episodes of ischemia/ reperfusion that render the heart more resistant to a major ischemic/ reperfusion event 
causing IRI. Preconditioning consists of two distinct phases: the early phase, which develops within a few 
minutes from the exposure to brief cycles of ischemia/reperfusion and lasts for 1–2 h; and the late phase, 
which develops within 6–12 h, and lasts for 3–4 days [2–6]. The early phase is capable of limiting myocardial 
infarction, while the late phase protects against both myocardial infarction and reversible myocardial 
dysfunction. In ischemic postconditioning, protective endogenous mechanisms are activated by very brief 
episodes of ischemia/ reperfusion applied immediately after a major ischemic/reperfusion event to render the 
heartmore resistant to reperfusion injury. In remote ischemic conditioning the application of one or more brief 
cycles of non-lethal ischemia/reperfusion to an organ or tissue protects a remote organ or tissue from a major 
episode of lethal IRI [7,8]. In remote ischemic conditioning the conditioning stimulus can be applied before 
(remote preconditioning), during (remote preconditioning), or after (remote postconditioning) a major 
ischemic event. Since the remote conditioning stimuli could be applied non-invasively by simply inflating and 
deflating a blood pressure cuff placed on a limb, this simplicity facilitates the translation of remote conditioning 
into the clinical arena as shown by several ongoing clinical studies. 
1.2. Cellular mechanisms of cardioprotection: importance of gene expression 
In the early phase after conditioning protocols, several signaling cascades are recruited including 
phosphorylative/dephosphorylative processes and redox signaling such as S-nitrosation/-nitrosylation, S-
sulfhydration, and O-linked glycosylation [6–9]. These processes converge on mitochondria improving their 
function and lead to modulation of gene expression profile after the conditioning stimuli. In fact, a transient (a 
few days) new synthesis of proteins due to upregulation of several cardioprotective genes, is mainly 
responsible for the protection afforded by late ischemic preconditioning. Mimicking the effect of ischemic 
conditioning through expression of cardioprotective genes would represent a therapeutic tool to limit infarct 
size of the heart and is an attractive research hypothesis worthy of consideration [9]. This type of gene 
expression would make the heart resistant to IRI for a long period. As of today, genes and signaling pathways 
by which conditioning exerts its effects on the heart are partially understood, due at least in part to the 
arbitrarily selected gene targets pursued so far that allowed identifying one or a few genes associated with IRI 
and with cardioprotection by conditioning. An alternative way to approach this fundamental issue is to use 
functional genomic approaches to identify genes that are differentially expressed in conditioning [10–12]. 
Genomics refers to the study of multiple genetic variants and/or gene expression profiles simultaneously [13, 
14]. Genomics utilizes technologies designed to elucidate hundreds to thousands of DNA variants (e.g., single-
nucleotide polymorphism [SNP] arrays/chips) as well as alterations in RNA expression levels (e.g., microarrays). 
Functional genomic analysis followed by analysis of alterations in protein levels (i.e., proteomics) and even final 
metabolic products (e.g., metabolomics) [14] could provide a global understanding of the cardioprotective 
genomic and proteomic program providing cardioprotection. The use of genome-based technologies allows for 
the interactive analysis of a collateral, cognate gene, thus leading to the identification of relevant processes 
and pathways involved in IRI and cardioprotection. Because thousands of gene products are analyzed 
simultaneously, intense mathematical analysis is required to interpret the final results. In this review, we 
describe how functional genomics may facilitate the identification of genes or gene sets/pathways that are 
associated with cardioprotection by conditioning. Then,we discuss someof the potential cardioprotective genes 
that could be or has been already targeted by gene therapy to mimic the cardioprotection afforded by ischemic 
conditioning (Table 1). 
 
2. Identification of potential cardioprotective target genes by analysis of cardiac gene expression profile 
In spite of 3 decades of research on the mechanism of cardioprotection, we still do not have cardioprotective 
drugs on the market. This is due to several reasons including the complexity of the cellular mechanism of 
cardioprotection which is far from being understood [7, 8,15]. Therefore, it is somehow surprising that a very 
small number of studies (compared to the thousands of studies on cardioprotection by conditioning) applied 
the functional genomics approach to reveal the complex mechanism of cardioprotection and to identify novel 
target genes to treat ischemic heart disease. Nevertheless, some studies have shown that both pre- and 
postconditioning significantly alter the gene expression profile of the ischemic heart at the transcript level. The 
first studies that described the effect of preconditioning on cardiac gene expression profile have been 
published a decade ago in rabbits [16] and rats [17]. These pioneer studies receive supportive information from 
several additional investigations showing that brief episodes of conditioning ischemia trigger a cardioprotective 
genomic response in the heart [18]. Moreover, recent studies have shown that ischemic postconditioning is 
able to modify the gene expression profile of mice [19] and rat hearts [20]. Expression profile of microRNAs, 
has been recently shown to bemarkedly changed by both pre- and postconditioning [21].  
So far no genomics approach has been applied to identify gene targets for remote conditioning, although 
extracellular vesicles, inter-organ carriers of microRNAs, have been recently identified as a potential mediator 
of remote conditioning [22]. The use of genomics-based technologies allows for the interactive analysis of 
collateral, cognate gene, thus leading to the identification of relevant processes and pathways involved in IRI 
and in cardioprotection by conditioning. Accordingly, Vincent et al., by using the DNA microarray technology, 
identified that the transcription factor ZAC1 gene is downregulated by both pre- and postconditioning [19]. 
Therefore, ZAC1 could be an interesting target for gene silencing. Varga et al. [21] made a systematic 
comparison in the direction of microRNA expression changes due to IRI between preconditioning and 
postconditioning, and they were able to identify protectomiRs, microRNA targets and specific mimics or 
antagomiRs of these targets that may have pre- and postconditioning-like cardioprotective effects. They 
termed these cardioprotective microRNA mimics or angatomirs as “protectomiRs”. By using this approach, the 
mimic microRNA 125b* has been identified and validated as a powerful cardio-cytoprotective protectomir. 
Based on the functional genomic approach, thousands of potential target genes can be identified by intense 
bioinformatic analysis of the results including several mathematical approaches such as e.g., network analysis 
[23]. It is encouraging to have more genomic studies to determine the complex cardioprotective genomic 
pattern and screen the key players to be targeted by gene therapy approach. Since the vast majority of the 
studies so far arbitrarily selected some potential gene targets to study in cardioprotection, the next chapters 
will review the most important cardioprotective genes identified so far by this traditional way. 
3. Gene therapy targeting nitric oxide synthase and cycloxygenase  
Up to now, the vast majority of the studies on cardioprotection has been based on arbitrary selection of 
potential target genes. The first gene identified as a mediator of late ischemic PC was the inducible isoform of 
nitric oxide synthase (iNOS) [24–26], which has been shown to increase modestly in cardiomyocytes within the 
ischemic–reperfused region after ischemic preconditioning. Subsequently, other genes involved in 
cardioprotection have been discovered, including cycloxygenase (COX)-2 [27], heme oxygenase (HO)-1 [28], 
antioxidant enzymes such as extracellular and manganese superoxidase dismutases (ec-SOD and Mg-SOD) [29], 
heat shock proteins (HSPs) [30,31], insulin like growth factor (IGF)-1 [32], antiapoptotic proteins such as Bcl-xL 
[33] and tumor growth factor (TGF)-alpha [34]. Li and colleagues [35] investigated short-term effects of iNOS 
gene transfer on myocardial IRI. The authors used adenovirus 5 (Ad5) vector with deletions of the E1, E2a and 
E3 regions, carrying the human iNOS gene (Ad5/iNOS) or control LacZ gene (Ad5/LacZ). Li and colleagues [35] 
compared the effects of iNOS gene transferwith that of late preconditioning by using a murine model of 
myocardial infarction, which was produced by a 30 min coronary occlusion followed by 4 h reperfusion. Gene 
transfer was produced profilactically 3 days before infarction, by intramyocardial injection in the anterior left 
ventricular wall of an adenoviral vehicle (PBS/1% sucrose) or Ad5/LacZ or Ad5/iNOS. Late preconditioning was 
produced by a sequence of six 4-min occlusion/4 min reperfusion cycles 24 h before the 30-min occlusion. In 
this model of gene therapy-mediated cardioprotection, it was demonstrated that intramyocardial injection of 
Ad5/iNOS resulted in a significant increase in iNOS protein expression, iNOS activity and nitric oxide (NO) levels, 
indicating effective transduction of myocytes with functionally competent iNOS. These effects were associated 
with a 67% reduction in infarct size compared with the control virus group (Ad5/LacZ). The role of 
cyclooxygenase (COX)-2 in the cardioprotection afforded by iNOS [27] was also investigated. Mice received an 
intramyocardial injection of Ad5/LacZ or Ad5/iNOS with additional administration of the selective COX-2 
inhibitor NS-398, 30 min before the coronary occlusion. Those mice had increased iNOS expression 
accompanied by increased expression and activity of COX-2. These effects were abrogated by coadministration 
of COX-2 selective inhibitor, thus demonstrating that COX-2 is an obligatory downstream effector of iNOS-
dependent cardioprotection. In a following work, Li and colleagues [36] investigated the long-term effects of 
iNOS gene therapy on cardiac function after myocardial injury. Gene transfer of iNOS was produced one or two 
months before infarction (30-min coronary occlusion followed by 4 h of reperfusion), by using the same 
recombinant Ad5 vector employed in the previous study. In mice transduced with Ad5/iNOS, infarct size was 
smaller than in the control virus group (Ad5/lacZ) at either 1 month and 2 months after gene transfer, 
demonstrating that the expression of iNOS was associated with long-term cardioprotection.  
4. Gene therapy targeting oxidative stress 
Considerable evidence indicates that reactive oxygen species (ROS), such as superoxide anion (O2•−), hydroxyl 
radical (HO•) and hydrogen peroxide (H2O2), contribute importantly to myocardial ischemia–reperfusion injury 
[37]. Li and colleagues [29] investigated the role of ec-SOD in myocardial protection, by using a conscious rabbit 
model of myocardial infarction [38,39]. However, ROS have been identified as essential cardioprotective 
signaling molecules either in pre or post-conditioning processes. The reasons of the switch from protective 
oxidative signaling to deleterious oxidative stress are not fully understood. The complex regulation of this 
switch is, at least in part, responsible for the diminished or absent cardioprotection by conditioning protocols 
observed in aging and in the presence of some comorbidities [8,40]. Since exogenous antioxidants in human 
trials failed to provide a beneficial result or even resulted in toxicity under certain conditions, it is likely that the 
endogenous antioxidant subcellular localization, the amount of ROS produced and the time course of their 
synthesis during ischemia/reperfusion could all be of primary importance for explaining the dual role of ROS 
and antioxidants. Authors postulated that gene therapy capable of creating an endogenous source of 
antioxidant enzymes, could limit lethal myocellular injury during ischemia–reperfusion in vivo. The infarction 
protocol in this study consisted of a 30 min coronary artery occlusion by placing a balloon occluder around a 
major branch of the left coronary artery, followed by 3 days of reperfusion. The effects of ec-SODgene transfer 
were compared with that of late preconditioning, which was realized with a sequence of six 4-min coronary 
occlusions interspersed with 4 min of reperfusion performed 4 h before the 30-min occlusion. It was shown 
that in the gene-therapy group, the average infarct size was 57% smaller than in the control-treated group, 
indicating the expression of ec-SOD as responsible for the marked cardioprotective effect, quite similar to that 
induced by the late phase of ischemic preconditioning. The protective role of antioxidant gene transfer in 
defense against ischemia–reperfusion injury, has been also investigated by Francis et al. [41] and Melo et al. 
[42]. Francis and colleagues proved that intramyocardial delivery of recombinant adenoviral vectors encoding 
for hemoxygenase 1 (HO-1) in a rat model of myocardial IRI, induced by ligation and release of the left anterior 
descending coronary artery, results in the prevention of myocardial infarct [41]. Melo and colleagues showed 
that intramyocardial delivery of recombinant adeno-associated virus encodingforHO-1 (AAV-HO-1)8weeks 
before coronary artery ligation and release, led to significant reduction of myocardial infarct size [42]. These 
effects were accompanied by a decrease of proapoptotic and proinflammatory proteins such as Bax and 
interleukin-1beta, respectively [42]. By using a similar model of intramyocardial gene delivery of a recombinant 
adeno-associated virus encoding for HO-1, followed by ischemia and reperfusion, Liu and colleagues analyzed 
the chronic effects of HO-1 gene delivery on myocardial fibrosis and remodeling after acute myocardial 
infarction [43]. They showed an amelioration of ejection fraction and left ventricular volumes at 1.5 months 
after HO-1 gene delivery, and significant reduction of myocardial scarring and fibrosis at three months [43]. The 
existence of positive effects of intramyocardial HO-1 gene deliverywas also confirmed in a different model of 
chronic recurring myocardial ischemia and reperfusion [44]. In this study, Pachori and coworkers delivered 
AAV-HO-1 five weeks in advance of the injury, followed by left coronary artery occlusion for 15 min and release 
performed daily for 5 days. The authors showed the prevention ofmyocardial wall thinning, inflammation, 
fibrosis and deterioration of cardiac function in the rats transduced with AAV-HO-1 [44]. By using a similar 
model of chronic recurring myocardial ischemia Liu and colleagues analyzed the chronic effects of HO-1 gene 
delivery on long-term survival, myocardial function and left ventricular remodeling 1 year after myocardial 
infarction [45]. The authors showed a significant reduction of mortality and greater recovery of left ventricular 
developed pressure and end-diastolic volumes in the HO-1-treated animals compared with LacZ-treated 
animals. Furthermore, morphometric analysis revealed extensive reduction of myocardial scarring and fibrosis 
in the infarcted area after HO-1 gene delivery [45]. Elevated levels of hypoxia-inducible factor (HIF)-1, a 
heterodimeric transcription factor composed by HIF-alpha and HIF-beta subunits, have been shown in rat brain 
and retina after a brief exposition to sublethal hypoxia. Date and colleagues [46] investigated the effects of 
adenovirus-mediated expression of HIF-1alpha in an in vitro model of preconditioning and IRI. Preconditioning 
was induced by placing cultured neonatal rat ventricular cardiomyocytes in a hypoxic chamber (1% O2, 5% 
CO2; 37 °C) for 3 h and then returning to control conditions (21% O2, 5% CO2, 37 °C) for 24 h, followed by 
simulated lethal ischemia (depletion of serum and glucose and hypoxia) for 2 h. Exposure to an episode of 
lethal hypoxia decreased cell death and increased mRNA levels of protective HIF-1 target genes such as 
Vascular Endothelial Growth Factor (VEGF) and HSP70. These effects of preconditioning were mimicked by 
preinfection of cultured cardiomyocytes with recombinant adenoviral vectors encoding for HIF-1alpha 
(Ad2/HIF-1alpha) 48 h before simulated ischemia–reperfusion. Cardioprotective effects of HIF-1alpha have 
been recently demonstrated by the codelivery of cardiac progenitor cells (CPC) with a nonviral minicircle 
plasmid carrying HIF-1alpha (MC-HIF-1alpha) in a murine model of myocardial infarction [47]. This has resulted 
in better recovery of ejection fraction 6 weeks after myocardial infarction in the hearts injected with CPC + MC-
HIF-1alpha. Targets for HIF are cardioprotective genes such as VEGF, iNOS, and erythropoietin, survivin and 
insulin growth factor binding protein [48]. Belke and colleagues [31] investigated the role of heat shock protein 
(HSP)-mediated adaptive response in limiting IRI. HSPs are a family of inducible and constitutive intracellular 
proteins, specifically expressed after exposure to heat and a wide spectrumof stressful and potentially 
deleterious stimuli such as brief ischemia (see for an extensive review: [49]). In the study by Belke and 
colleagues the role of viral-mediated gene therapy delivering HSP70 in the cardioprotection after ischemia–
reperfusion was investigated. By the direct injection of replication-deficient adenovirus type 5 vectors 
expressing HSP70 in the left ventricular free wall of a mouse heart, the authors were able to moderate 
functional loss and cellular damage (measured via creatine kinase release) following ischemia–reperfusion. 
Contractile function was measured in isolated Langendorff perfused hearts 5 days and 8 months following in 
vivo gene therapy. In preischemic aerobically perfuse hearts, developed pressure as well as the rate of 
contraction (+dP/dt) and relaxation (−dP/dt) did not differ between mice injected with adenovirus expressing 
HSP70 or those expressing empty vector. Following 20 min of ischemia and 120 min reperfusion, analysis of 
pressure tracings generated by the heart indicated a higher developed pressure in the HSP70 group (46% 
increase). Analysis of the rates of contraction and relaxation also showed a significant increase in the HSP70-
treated group. Analysis of creatine kinase release during reperfusion indicated a greater release of enzyme in 
the control group than in the HSP70 group, suggesting greater cellular damage in the control group. Belke and 
colleagues observed the protective effects of HSP70 also up to 8 months after gene therapy, demonstrating a 
potential therapeutic effect for chronic conditions. Previous work by Okubo and colleagues showed the 
cardioprotective effects of HSP70 in ischemic hearts [50]. Recombinant adenovirus encoding for the inducible 
form of human HSP 70 (Ad.HSP70), was injected in the ventricles, and such procedure was followed by 30 min 
ligation of the left coronary artery and 3 h reperfusion. The authors showed a significant reduction of infarct 
size in Ad.HSP70-injected hearts compared with the saline- and Ad.LacZ-treated hearts [50]. The 
cardioprotective effects of HSP70 in ischemic injury have also been found by Suzuki and colleagues, by using a 
different method of cardiac gene transfer [51]. The HSP70 gene was transfected by intracoronary infusion of 
the hemagglutinating virus of the Japan (HVJ)-liposome containing human HSP70 gene, and Langendorff 
perfusion was performed to evaluate the effect of HSP70 on myocardial protection. Hearts overexpressing 
HSP70 showed enhanced recovery of both systolic and diastolic cardiac function, as well as less damage after 
ischemia–reperfusion as compared with control. The study showed that gene therapy by HSP70 has a potential 
to enhance myocardial tolerance to ischemia better than the heat stress by itself [3]. In a similar model of 
HSP70 gene therapy by intracoronary infusion of the HVJ-liposome containing human HSP70 gene, Suzuki and 
colleagues [51] showed that the enhanced activity of mitochondrial manganese SOD (Mn-SOD) during 
ischemia–reperfusion injury, is one of the  possible mechanisms explaining HSP70-induced myocardial 
protection, likely by mitochondrial protection and apoptosis reduction [52]. After ischemia, Mn-SOD content 
and activity in the HSP70- transfected hearts enhanced compared to the controls, and this was further 
associated with improved mitochondrial respiratory function [51]. However, there is conflicting evidence about 
HSP70 expression within the atherosclerotic plaque. It has been reported that HSP70 expression is increased in 
necrotic plaques [53]. A more recent study reported no difference in HSP70 staining between fibrotic plaques 
and inflammatory plaques, whereas HSP70 expression was increased in plaques with thicker fibrous caps only 
[54]. This discrepancy may be due to the different stage of atherosclerotic development investigated. 
Nevertheless, due to the importance of this HSP70 in pro-survival signaling, the observed differences suggest 
caution andmore experimental studies are necessary to clarify the exact role of HSP70 in atherosclerosis before 
translating its overexpression in a clinical scenario. 
5. Gene therapy targeting angiogenesis 
Among target genes for HIF, PR39, a proline (P)- and arginine (R)-rich peptide with 39 aminoacids, is of great 
interest because of its effects in limiting cardiac injury through induction of angiogenesis [55]. Muinck and 
colleagues [56] investigated the role of PR39 in defense against IRI. The authors proved that intramyocardial 
delivery of recombinant adenoviral vectors encoding for PR39 in a murine model of myocardial ischemia–
reperfusion injury, induced by ligation and release of the left anterior descending coronary artery, resulted in a 
significant reduction of myocardial infarct size [56]. Since this effect was completely abolished after 
cotransfection with a PR39 adenovirus plus plasmid encoding a HIF-1alpha dominant negative construct (PR39 
+ HIF- 1alpha-dn), the authors showed that cardioprotection by PR39was likely conveyed by protective 
metabolic and survival responses through HIF- 1alpha stabilization and not by angiogenesis. Despite pro-
fibrotic effects, the active form of TGFbeta has been shown to exert cardioprotection in in vivo models of IRI 
[56], and also to decrease cell injury in an in vitro model of hypoxia-reoxygenation [57,58]. Dandapat and 
colleagues [34] investigated whether upregulation of a TGFbeta active form in vivo using adeno-associated 
virus type 2 would induce cardioprotection from IRI. Adenovirus-TGFbeta (AAV/ TGFbeta active) or adenovirus-
GFP was injected into 4 different sites in the left descending artery territory. After 6 weeks of intramyocardial 
injections rats were subjected to 60 min left descending artery ligation followed by 60 min of reperfusion. 
Following ischemia–reperfusion, AAV/TGFbeta active-overexpressing rats had a much smaller infarct size. In 
investigating the involvement of lipid peroxidation (measured by malondialdehyde levels in the myocardial 
tissues) in IRI, authors showed that overexpression of AAV/TGFbeta active significantly reduced IRI-induced 
lipid peroxidation,whichwas also related to reduced activation of NADPH oxidase and NF-kB. These data 
demonstrate that overexpression of TGFbeta by AAV can protect cardiac tissue from reperfusion injury, 
possibly via an antioxidant mechanism, suggesting the potential of TGFbeta active gene therapy for 
cardioprotection from IRI. Sphingosine kinase 1 (SPK1) has been identified as a central mediator of ischemia 
preconditioning; it plays a protective role in ischemia/reperfusion- induced cardiomyocyte death. Duan and 
colleagues showed that intramyocardial delivery of recombinant adenoviral vectors encoding for SPK1 in a rat 
model of myocardial IRI, resulted in significant reduction of myocardial infarct size [59]. Marked improvement 
of several functional parameters, such as left ventricular (LV) systolic pressure, LV end-diastolic pressure, and 
peak velocity of contraction (dP/ dt), was observed in the heart injected with SPK1, compared to saline and 
adenoviral control [59]. 
6. Gene therapy targeting antiapoptotic and autophagy genes 
Since IRI has been shown to elicit apoptosis of cardiomyocytes via the production of reactive oxygen species 
and mitochondrial damage, up-regulation of antiapoptotic genes or autophagy would be a further therapeutic 
approach for preventing myocardial damage. Autophagy is a housekeeping process that helps in maintaining 
cellular energy homeostasis and removes damaged organelles. In the heart, autophagy is an adaptive process 
that is activated in response to stress including acute and chronic ischemia [60]. Ischemia preconditioning has 
been shown to be causally associated with an increased number of autophagosomes in cardiomyocytes in 
hearts undergoing three cycles of 5 min regional ischemia alternating with 5 min reperfusion [61]. 
Cardioprotection from autophagy during ischemia preconditioning could be inhibited with dominant negative 
mutation of the autophagy protein Atg5 [61]. Several studies have shown that both the intrinsic and extrinsic 
apoptotic cell-death pathways are induced in the ventricular cardiomyocyte after myocardial 
ischemia/reperfusion, and that they converge with each other in the activation of caspase-3 [62–64]. It has 
been reported that cardiomyocytes can acquire resistance to IRI after brief ischemia through induction of anti-
apoptotic genes, such as Bcl-2 and Bcl-xL [25]. Kossmehl and colleagues [64] examined the expression of FasL, 
Bcl-2, Bax, caspase-3 and p53 in an isolated hemoperfused porcine working heart model of acute ischemia (2 
h), followed by reperfusion (4 h). The authors also analyzed the influence of the renin–angiotensin system 
(RAS) on an ischemia/reperfusion-induced programmed cell. In this model, Fas, Bax, Bcl-2, caspase-3 and p53 
proteins were increased during ischemia/reperfusion in the hearts, and further elevated by the administration 
of angiotensin I. The RAS inhibitor quinaprilat reduced Bcl-2, Bax, caspase-3 and p53 expression, but had no 
effect on Fas protein [64]. Gomez et al. [65] studied which of the Fas/FasL or the mitochondrial pathway has a 
predominant role in cardiomyocyte death after ischemia/reperfusion injury. The authors used amodel of 
genetic inactivation of the Fas receptor (lpr mice), pretreated with either saline or cyclosporin A [a desensitizer 
of the mitochondrial permeability transition pore (mPTP)], undergoing 25 min of ischemia followed by 24 h of 
reperfusion [65]. The authors found that control and lpr hearts exhibited a comparable increase in caspase-3 
activity, while cyclosporin A treatment significantly reduced caspase-3 activity in control and lpr hearts, 
suggesting that the Fas pathway likely plays a minor role, whereas mitochondria are preferentially involved in 
mice cardiomyocyte death after a lethal insult [47,65]. Huang and colleagues [33] investigated whether 
adenovirusmediated Bcl-xL gene transfer could provide a direct cardioprotective effect in the context of cardiac 
IRI. Adenovirus-mediated gene transfer into the heart was carried out by direct injection of adenoviral vector 
encoding human Bcl-xL (AdBclxL) into the anterior wall of the left ventricle four days prior to ischemia–
reperfusion injury. Three experimental groups were evaluated: saline control group injected with saline alone, 
LacZ group injected with adenoviral vector encoding LacZ, and Bcl-xL group injected with Bcl-xL gene. Rats were 
sacrificed 4 days after gene-transduction. 30 min ischemia followed by 30 min reperfusion at 37 °C were 
applied to the excised heart. In the in vivo protocol of ischemia–reperfusion, 4 days after the injection into the 
heart the left anterior descending coronary artery was ligated. After 30 min the suturewas released and 
reperfusionwas carried out. Ratwere sacrificed 24 h after reperfusion and infarct size was evaluated. In this 
model, adenoviral gene transduction did not affect cardiac performance such as coronary flow and dp/dt after 
ischemia–reperfusion protocol. Marked improvement of dp/dt recovery and coronary flow was observed in the 
heart injectedwith Bcl-xL, in comparisonwith saline and adenoviral control. A decrease of caspase-3 after 
ischemia–reperfusion injury was observed in the heart injected with Bcl-xL in comparison with saline and 
adenoviral control. This effect was accompanied by decreased apoptosis at the surrounding area outside the 
Bcl-transduced myocardium. In the in vivo protocol, a significant reduction of serum creatine kinase levels was 
observed in the animals treated with the myocardial Bcl-xL gene transduction.  
7. Gene therapy targeting PI3K–Akt pathway 
Dephosphorylation of FoxOs following deactivation of the PI3K–Akt pathway induces expression of cell death-
related genes, including FasL and Bim[66], which are phosphorylated by Akt. It is known that activation of the 
PI3K–Akt pathway by growth factors such as HGF has the potential to limit infarct size and determine 
cardioprotection, preventing or attenuating the activation of intrinsic and extrinsic apoptotic cell death 
pathways. This is potentially clinically relevant at the time of MI and post-MI reperfusion. Among growth 
factors with cardioprotective effects through the activation of the Akt pathway, IGF-1 and HGF are of great 
interest because of their effects in promoting cell growth and viability [32,67,68], in reducing apoptosis after 
transient ischemia in vivo [69–71], in reducing fibrosis [72] and inducing angiogenesis [73,74]. In an ex vivo 
model of IRI hearts Buerke and colleagues investigated whether adenovirus-mediated IGF transfer could 
provide cardioprotection. Adenovirus-IGF or LacZ were injected into the left ventricle apex and 48 h later rats 
were subjected to 30 min LAD ligation and 24 h reperfusion. LAD ligation produced a significant area of 
anteroapical infarction, which was not different among saline and LacZ, but significantly reduced in adenovirus-
IGF injected hearts. HGF, also known as scatter factor (SF) because of its property to induce the scattering of 
epithelial cells, consists of six domains: an amino-terminal domain (N), four kringle domains (K1–K4) and a 
serine proteinase homology (SPH) domain [75]. By using a rabbit model of ischemia– reperfusion injury, Chen 
and colleagues demonstrated that HGF/SF gene transfer is cardioprotective through its multiple beneficial 
actions, such as angiogenesis, Bcl-2 overexpression, and decreasing hydroxyl radicals, deoxyuride-5′-
triphosphate biotin nick end labeling (TUNEL)-positive myocytes, and fibrotic area [76]. The authors performed 
intraventricular injection of recombinant adenovirus encoding for HGF/SF (Ad.HGF/SF), followed by 30 min 
ligation of the left coronary artery and reperfusion for a minimum of 30 min to a maximum of 14 days. The 
authors showed a significant reduction of infarct size in Ad.HGF-injected hearts compared with saline- and 
Ad.LacZ-treated hearts [76]. At 14 days after reperfusion, HGF gene transfer improved left ventricular ejection 
fraction and fractional shortening, reduced the fibrotic area, and increased the capillary density in the risk area. 
At 4 h after reperfusion, Bcl-2 protein was overexpressed and the incidence of TUNEL-positive myocytes was 
significantly decreased in the risk area [76].  
8. Vectors useful for gene therapy 
The introduction of exogenous genes can be performed either by directly introducing the delivery vector [such 
as lentivirus or adenoassociated viral (AAV) vectors] into the anatomical site (in vivo) or by harvesting cells 
from the patient, transferring the gene(s) to the cells in tissue culture and then transferring the genetically 
modified cells back into the patient (ex vivo) (reviewed in [77]). The ex vivo approach typically relies on 
transplanting cells, such as stem cells, lymphocytes, fibroblasts, or – alternatively – the cells of interest, that are 
removed from the body and injected after therapeutic transgene modifications. This ex vivo approach allows 
for targeting of specific cells for gene delivery, supplies cells that may directly participate in the regenerative 
process, allows for both autocrine and paracrine effects fromthe expressed growth factor, and avoids the 
safety risks of directly injecting viral vectors or transfection reagents in vivo. This approach, however, involves 
an extra step to manipulate and expand cells in culture, and has the risk of contamination. Additionally, the ex 
vivo approach does not eliminate the possibility of retroviral vectors causing insertional activation of other 
genes, the over-expression of which may cause cancer. The in vivo gene delivery approach is more 
straightforward, but is limited by inefficient gene delivery, nonspecific cellular targeting, the complexity of 
cloning and integrating the gene into the target cells and safety and efficiency of transduction. With respect to 
the delivery of growth factors (GFs), a possible drawback of the use of lentiviral and AAV vectors for delivering 
genes that encode for GFs might be that they can cause a chronic overexpression of the protein,with an 
uncertain therapeutic effect. Short-term gene expression of the GF gene (by plasmid transfection or adenoviral 
vectors) would be desirable if the goal is to deliver a secreted protein, such as IGF-1, vascular endothelial 
growth factor (VEGF) and HGF, while long-term expression would be preferable if the goal is to express 
membrane proteins such as receptors for growth factors that require stable expression. Limitations of these 
strategies are the low transfection efficiency with plasmids and the immunogenic response of the host against 
the adenoviruses. 
9. Conclusions and perspectives 
Gene therapy may offer a novel, effective strategy for the management of cardioprotection in ischemic cardiac 
disease. Preclinical studies have shown the potential of gene therapy for protecting the heart against acute 
myocardial ischemia through mimicking ischemic conditioning. AAV seems particularly suitable to address the 
last requirement, since they have shown specific tropism for cardiomyocytes, and a capability to drive the 
expression of the delivered genes in these cells for a long time. However, to date, there have been no well-
controlled long-term studies in the preclinical area. Hence, we cannot make any conclusive statements about 
the clinical suitability/efficacy of gene delivery in humans. The crucial issues that are still to be resolved prior to 
achieving clinical success include the understanding of whether protected cells might be obtained as a result of 
the delivery of a single factor orwhether protected cells might require more complex gene combinations, the 
identification of the proper timing of therapeutic gene expression and, probably, the development of more 
efficacious gene delivery tools that allow a time-controlled gene delivery and expression. If resolved, 
cellmediated synthesis of cardioprotective gene modulators might offer more efficient targeting of receptors 
and, consequently, a more robust and predictable approach in cardioprotection. Nonetheless, accumulating 
data from the genomic studies of ischemic conditioning encourage investigators to further identify novel gene 
targets for cardioprotection.  
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